{"doi":"10.1093/ajh/4.2.181s","title":"Beneficial Effects of the Calcium Antagonist Isradipine on Apolipoproteins in Hypertensive Patients","abstract":null,"journal":"American Journal of Hypertension","year":1991,"id":626089,"datarank":0.26876392038420827,"base_score":1.791759469228055,"endowment":1.791759469228055,"self_citation_contribution":0.26876392038420827,"citation_network_contribution":0.0,"self_endowment_contribution":0.26876392038420827,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1619454,"name":"Claude Gagné","orcid":null,"position":1,"is_corresponding":false},{"id":1619455,"name":"Daniel Brun","orcid":null,"position":2,"is_corresponding":false},{"id":1619456,"name":"Luc Poirier","orcid":null,"position":3,"is_corresponding":false},{"id":1619457,"name":"Danielle Dion","orcid":null,"position":4,"is_corresponding":false},{"id":1619458,"name":"Christopher Yardley","orcid":null,"position":5,"is_corresponding":false},{"id":1619453,"name":"Yves Lacourcière","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Beneficial Effects of the Calcium Antagonist Isradipine on Apolipoproteins in Hypertensive Patients","abstract":"The objective of the study was to assess the effects of the calcium antagonist isradipine on plasma lipids, lipoproteins, and apolipoproteins in patients with essential hypertension. After a four-week placebo wash-out period, 73 patients (41 men, 32 women) were studied in a double-blind, randomized, crossover study comparing sustained-release isradipine (isradipine SR) with the standard isradipine formulation. Nineteen patients received 5 mg/day and 54 patients 10 mg/day. Lipids were evaluated at the end of the placebo period and after 12 weeks of treatment with isradipine. In both treatment groups, lipid and lipoproteins were not modified. However, apolipoprotein A-I levels increased significantly (P less than .001) and the ratio of apolipoprotein B to apolipoprotein A-I concentration decreased significantly (P less than .01) irrespective of gender. These data show that the levels of plasma apolipoprotein A-I, a strong predictor of coronary heart disease, are favorably affected by isradipine of either formulation. The mechanisms of this effect remain to be elucidated.","is_dataset_classified":null,"base_score":1.791759469228055,"endowment":1.791759469228055,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"1827016","pmcid":null,"openalex_id":"https://openalex.org/W2407779798","authors":[],"funders":[],"total_grants":0,"fwci":0.7876,"citation_percentile":0.72271319,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://academic.oup.com/ajh/article-pdf/4/2_Pt_2/181S/415360/4-2_Pt_2-181S.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1093/ajh/4.2.181s","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/1827016","host_type":"repository"}],"fields_of_study":["Diabetes, Cardiovascular Risks, and Lipoproteins","Pharmaceutical Practices and Patient Outcomes","Lipoproteins and Cardiovascular Health","Adult","Aged","Apolipoproteins","Calcium Channel Blockers","Dose-Response Relationship, Drug","Double-Blind Method","Female","Humans","Hypertension","Isradipine","Lipids","Lipoproteins","Male","Middle Aged","Prospective Studies","Pyridines"],"mesh_terms":["Adult","Aged","Apolipoproteins","Calcium Channel Blockers","Dose-Response Relationship, Drug","Double-Blind Method","Female","Humans","Hypertension","Lipids","Lipoproteins","Male","Middle Aged","Prospective Studies","Pyridines","Isradipine"],"keywords":["Isradipine","Medicine","Apolipoprotein B","Placebo","Crossover study","Internal medicine","Antagonist","Endocrinology","Calcium","Lipid profile","Pharmacology","Cholesterol","Dihydropyridine","Receptor"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T12:23:45.081929Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}